Kingswood Wealth Advisors LLC Reduces Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Kingswood Wealth Advisors LLC reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 8.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,949 shares of the company’s stock after selling 577 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Moderna were worth $634,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Allworth Financial LP grew its stake in Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the period. TIAA Trust National Association increased its stake in shares of Moderna by 2.3% in the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after acquiring an additional 102 shares in the last quarter. Sound Income Strategies LLC increased its stake in shares of Moderna by 17.8% in the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after acquiring an additional 115 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after acquiring an additional 116 shares during the period. Finally, Geo Capital Gestora de Recursos Ltd boosted its stake in Moderna by 0.4% during the fourth quarter. Geo Capital Gestora de Recursos Ltd now owns 32,339 shares of the company’s stock worth $3,216,000 after acquiring an additional 144 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of analyst reports. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Royal Bank of Canada boosted their target price on Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, June 3rd. Canaccord Genuity Group raised their price target on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday, May 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Monday, June 3rd. Finally, UBS Group raised their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $129.02.

Moderna Stock Performance

MRNA stock opened at $122.45 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The business’s 50-day moving average is $133.40 and its two-hundred day moving average is $111.40. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business’s quarterly revenue was down 91.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.19 EPS. On average, research analysts forecast that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00. Following the transaction, the director now directly owns 2,086,931 shares of the company’s stock, valued at approximately $212,199,144.08. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Moderna news, President Stephen Hoge sold 255 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the transaction, the president now directly owns 1,486,508 shares in the company, valued at $179,808,007.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00. Following the completion of the sale, the director now directly owns 2,086,931 shares of the company’s stock, valued at $212,199,144.08. The disclosure for this sale can be found here. Insiders have sold 396,255 shares of company stock worth $54,210,631 in the last 90 days. 15.70% of the stock is currently owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.